FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of May 2025
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
Director/PDMR Shareholding
23 May 2025 10:00
Transaction by Person Discharging Managerial
Responsibilities
AstraZeneca PLC (the Company) announced that, on 21 May 2025, an
award of the Company's ordinary shares of $0.25 each (Ordinary
Shares) vested to Pascal Soriot, Executive Director and Chief
Executive Officer, under the terms of the AstraZeneca Performance
Share Plan (AZPSP).
The AZPSP award was granted on 21 May 2020 as part of the award
granted to Mr Soriot on 6 March 2020, and reflected the revised
limits of the AZPSP, as approved by shareholders at the Company's
2020 Annual General Meeting. The award was subject to a three-year
performance period. On the third anniversary of grant the award was
placed in a two-year holding period. The award vested at the end of
that holding period. Application of the performance measures
specified at the time of the grant resulted in 97% of the AZPSP
award vesting and the remaining unvested part lapsing.
Following the reinvestment of dividends accrued during performance
and holding periods of the AZPSP award, and the withholding of
shares to satisfy certain tax obligations arising on vesting, Mr
Soriot's beneficial interests in Ordinary Shares changed as
detailed in the table below:
|
PDMR
|
Ordinary Shares acquired under the AZPSP
|
|
Pascal
Soriot
|
8,970
|
For tax purposes, the fair market value of an Ordinary Share at
vest of the AZPSP award was 10,418 pence, being the
closing price on the last trading day preceding the
vesting.
Further details are set out in the attached notification, made in
accordance with the requirements of the EU Market Abuse Regulation
(as it forms part of UK law pursuant to the European Union
(Withdrawal) Act 2018.
|
1
|
Details of the person discharging managerial responsibilities /
person closely associated
|
||
|
a)
|
Name
|
Pascal
Soriot
|
|
|
2
|
Reason for the notification
|
||
|
a)
|
Position/status
|
Chief
Executive Officer
|
|
|
b)
|
Initial notification /Amendment
|
Initial
notification
|
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
AstraZeneca
PLC
|
|
|
b)
|
LEI
|
PY6ZZQWO2IZFZC3IOL08
|
|
|
4
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
||
|
a)
|
Description of the financial instrument, type of
instrument
Identification
code
|
Ordinary Shares of US$0.25 each in AstraZeneca PLC
GB0009895292
|
|
|
b)
|
Nature of the transaction
|
Acquisition
of ordinary shares pursuant to a vesting under the AstraZeneca
Performance Share Plan, for nil consideration.
|
|
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
|
0
|
8,970
|
||
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
Not applicable - single transaction
|
|
|
e)
|
Date of the transaction
|
21 May
2025
|
|
|
f)
|
Place of the transaction
|
Outside
a trading venue
|
|
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca's innovative
medicines are sold in more than 125 countries and used by millions
of patients worldwide. Please visit astrazeneca.com and
follow the Company on social media @AstraZeneca
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Matthew Bowden
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
AstraZeneca
PLC
|
Date:
23 May 2025
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|